Combined Encorafenib-Binimetinib-Cetuximab therapy associated with longer overall survival in patients with BRAF V600E-mutated coloreactal cancer
1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) ...